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Aside from the normal, sporadic turnover of epithelial cells
along the adult nephron, most somatic cells in the kidney do not
divide, or if they are obligated to respond to an external
stimulus, there seems to be less hyperplasia in preference for
cellular hypertrophy. A variety of pathophysiologic stimuli
which provide temporary or permanent fixed reductions in renal
function often result, for example, in compensatory enlarge-
ment of the kidney, principally in the tub ulointerstitium [11.
Such adaptive responses are thought to provide a mechanism
for redressing initial damage, as well as providing for a limited
restoration of function. The renal hemodynamic alterations
associated with these events, like increases in single nephron
glomerular filtration rate (SNGFR) and glomerular blood flow,
have been extensively reviewed elsewhere [2, 3]. Changes in
the size of the tubular nephron, as well as subsequent, late renal
fibrosis have traditionally been considered a response to mod-
ifications in the mechanics of filtration—the so-called work
hypothesis [4]. There is, however, alternative evidence in
animals [5, 6], and humans [7], that the cellular processes of
compensatory renal enlargement, themselves might share in the
responsibility for the continued, long-term loss in remaining
nephrons.
Careful assessment of early enlargement parameters, like de
novo synthesis of phosphatidyicholine, reveal for example, that
some biochemical alterations occur earlier than the increase in
SNGFR, or can be dissociated from semi-concurrent hemody-
namic changes [8, 9]. Recent studies also provide evidence that
growth factors can directly modulate renal hemodynamics,
consistent with a contemporary view that initial compensatory
responses might be responsible for subsequent alterations in
hemodynamic parameters [10, 11].
The nature of the adaptive response of nephrons depends on
the age of the individual, and whether the underlying initial
insult is chronic or more acute. Tubular epithelial cells, for
example, respond to acute tubular necrosis with proliferation
and mitogenic activity, as defined by an increase in DNA
synthesis. The renal growth response in neonatal animal follow-
ing injury is also hyperplastic. Chronic damage of the adult
kidney, in contrast, leans more towards compensatory renal
hypertrophy with an increase in size and a rise in the protein!
DNA ratio.
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In the 1960s, the view that approximately 75 to 80% of
compensatory renal enlargement in adults was cellular hyper-
trophy, and the remaining 25 to 20% hyperplasia, is still widely
held today [12]. While most anatomical parts of the nephron are
probably involved in compensatory hypertrophy, the fact that a
major constituent of kidney mass is proximal tubules suggests
that an increase in size and protein content of proximal tubular
cells may principally contribute to compensatory renal hyper-
trophy [13]. The present article, therefore, will examine some of
these early-onset mechanisms of tubulointerstitial changes.
Table 1 gives an overview of currently used experimental
models of compensatory renal enlargement. Most models,
particularly the ablative ones, result mainly in renal hypertro-
phy. Others, like the induction of acute tubular necrosis in
animals by folate injection, however, are characterized by a
mitogenic response producing hyperplasia [1, 14].
Despite the existence of a burgeoning literature dealing with
more biochemical aspects of renal enlargement [14—16], the
molecular mechanisms involved in the regulation of such
changes are not formally understood. Especially incomplete is
an understanding of the nuclear and cytoplasmic regulation of
genes differentiating compensatory renal hypertrophy from true
hyperplasia. Recent discoveries in the fields of epithelial growth
factors, signal transduction and gene activation, however, have
shed some new light on the molecular mechanisms of cellular
enlargement. We will focus on these more recent findings.
Cell cycle
Cells undergoing mitotic divisions can be considered, in a
simplified model, as progressing through an orbit of successive
phases [17, 18]. These different phases include a stage of
enlargement, associated with an increase in protein content, in
order to prepare for DNA replication (G1-phase), DNA repli-
cation (S-phase), a post-replication phase of preparation for
division (G2-phase), and finally the mitosis (M) which can be
viewed as a cell cycle within itself [19]. The G1-phase lasts for
several hours in many cells with subsequent events seeming to
happened sequentially. A poorly defined level of competence in
such cells has been traditionally proposed as a requirement for
entering the G1-phase [20]. Competent cells can enter the
G1-phase of the cell cycle without any protein synthesis. They
progress towards the S-phase until they reach a special point
called V, also named START in budding eukaryotic yeast. After
this point rapid protein synthesis is necessary for the further
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Table 1. Some in vivo models of renal hypertrophy and hyperplasia
Hypertrophic responses
Renal ablation in adult animals
Unilateral obstruction (contralateral kidney)
High protein intake
Diabetes mellitus (insulin dependent)
Ammonium chloride feeding
Testosterone administration in female animals
Thyroxine administration
Combined hypertrophic and hyperplastic responses
Renal ablation in neonatal animals
Tubular salt overload
Deoxycortocosterone acetate with normal salt diet and furosemide
Potassium depletion
Hyperplasia response
Folate nephropathy
Chemical nephrotoxicity (mercuric chloride, lead acetate)
progression. This part of the G1-phase may not be dependent on
the presence of growth factors [21, 22].
Cell cycle regulation is probably not identical among all
species. In eukaryotic yeast, like S. cerevisiae, progression
through the cell cycle is controlled at the START point between
G1IS transition, whereas mammalian cells seem to have control
points at G1IS and G2/M. Recent studies have isolated factors
which are involved in the regulation of such control points.
MPF (maturation phase promoting factor) is a non-species-
specific mitotic inducer which can only be detected in cells
undergoing mitosis [23]. The catalytic subunit of MPF is a
34,000 Mr phosphoprotein with kinase activity called pp34 [24].
While originally identified as products of the cdc2 gene from
the fission yeast S. pombe, it has become very clear that other
eukaryotic mammalian cells, including humans, have similar
genes encoding for proteins homologous to pp34 [25—271. It is
now apparent that pp34 is responsible for the histone Hl kinase
activity of MPF which phosphorylates and activates histones
Hi [28]. The other subunits of MPF are the cyclins which can
be separated into cyclin A and B, sharing 31% amino acid
homology [29]. Cyclins accumulate during interphase, and
undergo degradation at the end of each mitosis, associated with
a drop in MPF activity [30].
The complex regulation of MPF has become more clear with
recent experiments in yeasts and in various mammalian tissues
[31]. S. pombe needs cdc2 activation for passage through
START, and for the induction of mitosis [24]. The control
protein pp34 is inactive when its is phosphorylated. During
mitosis threonine and tyrosine residues of pp34 are dephospho-
rylated resulting in increased activity of pp34 [32].
The factors which regulate the phosphorylation of pp34 are
unknown, but in yeast, expression of the gene cdc25 activates
pp34 [33], whereas the product of the weel gene, which has
homology with other protein kinases, inhibits pp34 [34]. The
level of pp34 is constant during the cell cycle, whereas cyclin
must accumulate during interphase. Cyclin forms with phos-
phorylated, inactive pp34 as a complex that still has no MPF
activity [18]. Dephosphorylation of pp34 and phosphorylation
of cyclin is necessary for MPF activity and entry into mitosis.
After activation of pp34, through dephosphorylation, probably
pp34 itself phosphorylates cyclin. Possible substrates for pp34
include Hi histones, lamins, nucleolin, and pp6Oc [17]. Phos-
phorylation of lamins is transient (only during mitosis), and is
required for the breakdown of the nuclear envelope and reor-
ganization of the cytoskeleton during mitosis [17]. Activated
MPF induces the degradation of cyclin leading to the return to
the interphase [18]. The regulation of cyclin degradation is
complex and may involve a factor called IMF (inhibitor of
MPF) [18, 35]. It has been suggested that in a similar fashion as
at the G2IM transition, pp34 interacts with a cyclin-like mole-
cule to induce protein kinase activity at START, the control
point of G1IS transition [18]. Thus, all major control points of
the cell cycle are regulated by an interaction between pp34 and
different cyclins, in which the activation of pp34 through
dephosphorylation is a key step in the regulation of cycling
events [361.
The majority of renal tubular cells do not normally undergo
repeated rounds of cell duplication. They rather remain in a
quiescent state, with a normal complement of DNA (G0-phase/
2n), where they carry out their multiple biochemical cell func-
tions [22]. The G0-phase can be recreated in cell culture through
deprivation of serum mitogenic factors. After the addition of
serum, or serum-derived growth factors, many cells in the
G0-phase re-enter the cell cycle and resume proliferation. In
vitro studies have shown that, shortly before the onset of the
S-phase, cell cycle events become independent of growth
factors in the remaining phases of the cycle. In mitogenic renal
growth responses, for example after acute tubular necrosis,
tubular epithelia begin to enter from the normal G0-phase of the
cell cycle, replicating their DNA in the S-phase and dividing.
The result is hyperplasia regeneration. In renal hypertrophy, to
the contrary, cells entering from the G0-phase, do not progress
to DNA-replication (S-phase). The mechanisms of arresting
cells in the G1-phase, that is, keeping pp34 phosphorylated [36],
are unclear. Possible events which might contribute to such a
process will be described below.
Tubulointerstitial environment
Several types of cells, including tubular epithelium, a variety
of interstitial cells (Type I and II in the cortex, types Ito III in
the medulla), interstitial fibroblasts, vascular endothelium,
macrophages and several phenotypes of lymphocytes, consti-
tute the cellular registry of the tubulointerstitial microenviron-
ment [37]. While tubular cells located along the nephron are
known to be discretely differentiated in various phenotypes,
recent findings also suggest that interstitial kidney fibroblasts
are a distinct population of cells adapted to the tubulointerstitial
microenvironment. These kidney fibroblasts have growth prop-
erties and biosynthetic characteristics of matrix proteins which
can be distinguished from syngeneic dermal fibroblasts [38—41].
Activated fibroblasts also secrete cytokines which are mitogen-
ic for tubular cells [41], and likewise, tubular cells release
proliferative cytokines for fibroblasts, like insulin growth factor
[42]. Resident macrophages and lymphocytes localized in the
tubulointerstitium can secrete cytokines like interferon, inter-
leukins (IL- 1-6), platelet-derived growth factors (PDGF), tumor
necrosis factor (TNF), transforming growth factor alpha
(TGFa) and transforming growth factor beta (TGF/3) [43, 44].
Somatic cells of the tubulointerstitium can be immune regulated
by mononuclear cells [43, 45]. Cytokines like interleukin 1
(IL-i) and TNF are also important modulators of vascular
endothelial growth [46]. Endothelial cells, themselves, are
capable of synthesis and secretion of IL-i, PDGF, granulocyte-
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macrophage colony stimulating factor (GM-CSF), interferon-
alpha, and TGFI3 which, in turn, can modify the proliferative
response of other cells located in the tubulointerstitium [46—48].
Thus, close interactive effects between different cell types,
sharing a complex cytokine network in the tubulointerstitial
microenvironment, can readily modify the rate of cell division
and size of their phenotypic neighbors.
Growth factors
Dating back into the fifties [49] and even more recently [501,
attempts have been made to characterize specific regulators of
renal hypertrophy circulating in the plasma, particularly after
uninephrectomy. These substances have been called renotro-
pins. Although there is evidence that such factors might exist,
the results of these studies are somewhat inconclusive. Some of
these factors, for example, may be similar to the polypeptide
growth factors described in detail below. The isolation, purifi-
cation and cloning of growth factors and their receptors,
however, along with new insights into the signal transduction
pathways coupled to those receptors, have provided a contem-
porary knowledge regarding cellular and molecular mechanisms
of renal enlargement.
There is increasing evidence for a physiological and/or patho-
physiological function for such cytokines in renal enlargement
[51, 52]. Tubular cells can secrete several of these growth
factors and they, and other renal interstitial cells, have recep-
tors for many of these factors [53, 541. Therefore, the local
release of growth factors may modulate tubular enlargement in
an autocrine and/or paracrine manner. Moreover, a change in
number or affinity of growth factor receptors, the interaction
with cytokines released by monocytes/macrophages, fibroblast
and endothelium, the endocrine circulation of growth promot-
ing hormones and finally, the local degradation of these factors
collectively create a complicated interactional picture [55].
Although the establishment and culture of several tubular cell
lines in serum free medium has promoted the investigation of
growth factor effects on cellular proliferation and hypertrophy
[56, 57], the contributions of a single growth factor to the whole
framework of renal enlargement in vivo remains to be estab-
lished. In defined serum-free media, however, some growth
factors, including epidermal growth factor (EGF), PDGF, and
TGFa are mitogenic [51, 57], and induce proliferation in cul-
tured tubular cells, while other factors such as insulin-like
growth factor I (IGF-I), insulin, TGF/3, prostaglandin E2, and
angiotensin II have been reported to preferentially induce
cellular hypertrophy [58—60]. Most growth factors probably
mediate the transition from G0 to G1 in quiescent cells.
Platelet-derived growth factor (PDGF)
Human PDGF is a heterodimer of A (14 to 18,000 Mr) and B
(16,000 Mr) chains linked together by disulfide bridges [61].
Both chains are synthesized as larger precursors and subse-
quently processed into functional moieties [62, 63]. The
PDGF-B chain is nearly identical with the product of the c-sis
oncogene [64, 65]. The extracellular domain of the PDGF-
receptor consists of 80 to 100 amino acids resembling immuno-
globulin domains in its secondary structure. Two different
genes for PDGF-receptors have been described whose products
demonstrate different responses to the PDGF subtypes [66].
Although PDGF is normally released from alpha-granules in
platelets [65], recent findings indicate that PDGF is produced by
epithelial kidney BSC-l cells, macrophages/monocytes and
endothelium [67, 68]. Adenosine diphosphate is also able to
stimulate c-sis expression and release of PDGF in that system.
Interestingly, BSC-l cells do not respond to PDGF in vitro with
mitogenesis, implying perhaps a paracrine mechanism of
PDGF-mediated proliferation. PDGF is mitogenic for kidney
endothelial and epithelial cells, and renal fibroblasts derived
from the tubulointerstitium. PDGF, furthermore, can stimulate
the release of other growth factors like IGF-I from fibroblasts
[65].
Epiderinal growth factor (EGF)
Mouse EGF is synthesized as a prepro-precursor molecule of
1217 amino acids which is inserted into the membrane as a
transmembrane protein [69—711. The cellular c-mos oncogene
shares sequences with pro-EGF. Specific proteases release the
active factor resulting in a single chain polypeptide of 53 amino
acids [72]. Human and mouse EGF have about 70% amino acid
homology [73]. The main sites of EGF synthesis in adult mice
are the kidney and the salivary gland, but other tissues might as
well produce EGF [70]. More than 90% of urinary EGF activity
is derived from renal synthesis [74, 75]. EGF immunoreactivity,
and in prepro-EGF mRNA transcripts, using in situ hybridiza-
tion, are localized to the thick ascending limb of Henle and the
distal convoluted tubule, but not to the proximal tubule [76—78].
Ultrastructural investigation shows the presence of EGF in
luminal membranes and apical vesicles [79]. Specific receptors
for EGF have been demonstrated in the basolateral membrane
of the proximal tubule and in a variety of different cell lines
originating from the proximal tubule [80, 81]. The EGF-receptor
is a 170,000 Mr protein with intracellular tyrosine kinase
activity [82]. Interestingly, thyroid and growth hormone can
induce hepatic EGF-receptors, providing one mechanism for
how endocrine hormones can modify the action of local growth
factors [83, 841. In contrast, interferon a downregulates EGF
receptors on Madin-Darby bovine kidney cells, explaining in
part the growth inhibitory effects of interferon [85]. EGF is
mitogenic for tubular epithelial cells in culture [57, 86]. More-
over, EGF can inhibit gluconeogenesis in proximal tubules [81].
Renal ischemia reduces prepro-EGF mRNA levels, but in-
creases the number of EGF receptors [87]. Infusion of EGF
enhances recovery from acute tubular necrosis [88]. These
findings indicate that intra-renal EGF might modulate the
mitogenic response after acute tubular necrosis. Immunostain-
able EGF in the apical cell parts of the distal tubule also
continuously increases up to two weeks after uninephrectomy
[891. An increase in immunoreactive EGF and prepro-EGF
mRNA transcripts were observed in the remnant kidney seven
days after uninephrectomy, indicating that increases in intra-
renal EGF synthesis is a rather late event in the time course of
compensatory renal growth [901. Binding of EGF to basolateral
tubular membranes was decreased three weeks after uninephrec-
tomy, which might likely indicate a down regulation of its
receptor [91]. Mice made deficient of circulating EGF by
sialoadenectomy also fail to undergo compensatory renal
growth after unilateral nephrectomy. Exogeneous EGF replace-
ment restored the growth response [92]. Other investigators,
however, have found no difference in EGF receptor density
between controls and rats receiving uninephrectomy [93]. The
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hyperplastic regeneration of tubules following folic acid admin-
istration was associated with an upregulation of EGF receptors
[93]. Since EGF is a mitogen in vitro for tubular epithelial cells,
the real role of EGF in renal hypertrophy remains uncertain.
Insulin-like growth factors (IGFs)
IGFs share approximately 50% homology with pro-insulin.
IGF-I (Somatomedin C) and IGF-II (Somatomedin A) have 62%
homology [94]. Both factors are monomeric polypeptides which
are cleaved from larger precursors. IGF-I contains 70 amino
acids whereas IGF-II is composed of 73 amino acids [95]. The
human IGF-I gene consists of five exons localized on chromo-
some 12 [96]. The IGF-II gene is composed of seven exons and
maps to chromosome 11 [97]. Alternative splicing of mRNAs of
both genes occurs. IGF-I is produced in many tissues, including
the kidney where it localizes to mesangial cells and principal
cells of the collecting duct [98, 99]. The production of IGF-I is
stimulated by pituitary growth hormone (GH) 1100]. IGF-II
mRNA can also be detected in the kidney and may be involved
in growth regulation of the developing fetal nephrons [101]. The
receptor for IGF-I (type I IGF receptor) consists of two
peptide-binding alpha-subunits and two beta-subunits with ty-
rosine kinase activity [102]. The IGF-I receptor and the insulin
receptor share 80% identity in the tyrosine kinase domain. The
receptor has three times lower affinity for IGF-II and a low
affinity for insulin [103]. Peptide binding to the receptor results
in autophosphorylation of the beta-subunit. A second IGF
receptor (type II IGF receptor) is present in almost all cell
types. This receptor has a higher affinity for IGF-II than IGF-I,
and also does not bind insulin [104]. The type II IGF receptor
shares a high sequence homology with a membrane lectin-like
receptor for mannose-6-phosphate, and consequently, can bind
proteins with mannose 6-phosphates, although only at a dif-
ferent molecular site than IGF [105]. The IGF-II receptor is a
single peptide with an extracellular domain connected through a
transmembrane segment to a cytoplasmic region composed of
164 amino acids without any similarity to known sequences.
IGF-II probably mediates its mitogenic effects through the type
I IGF receptor, since antiserum against the IGF-II/mannose
6-phosphate receptor can not block mitogenic activity of IOF-
II. IGF-I receptors which undergo autophosphorylation after
IGF-I binding have been detected on the basolateral membrane
of the proximal tubule [106]. In addition, IGF-I receptors with
several-fold less binding capacity, and without signal transduc-
tion activity are localized in luminal membranes of the proximal
tubule. IGE-Il receptors are also localized in basolateral and
brush border membranes [107]. IGF-I has also been found in
regenerating S3 segments of the proximal tubule after acute
ischemic injury in rats [108]. The immunoreactivity of IGF-I
decreases and finally vanishes with increasing differentiation of
regenerating cells. Stiles and co-workers demonstrated an in-
crease in immunoreactive IGF-I extracted from whole kidneys
five days after uninephrectomy [109]. In hypophysectomized
animals, the increase of IGF-I was of the same magnitude, but
from lowered basal IGF-I levels. In another study, an increase
of kidney extracted IGF-I of 58% over controls was found after
24 hours. A similar increase of IGF-I was demonstrated in rats
made diabetic by streptozotocin treatment [110], and 24 hours
after uninephrectomy in Wistar rats [111]. Feeding the rats a
low (8% casein), but not a medium or high (78% casein) protein
diet before nephrectomy, blunted the increase of IGF-I in the
remnant kidney. Renal IGF-I content was not different among
sham-operated animals on the different diets. A report by the
same group showed that dwarf rats deficient in OH increase
their acid extractable renal IGF-I and undergo compensatory
renal enlargement after uninephrectomy [112]. More recently, a
fivefold increase in mRNA transcripts for IGF-I, using dot-blot
hybridization, was observed 24 hours after unilateral nephrec-
tomy in the rats [113]. This increase was sustained for one week
and occurred in the absence of any changes in circulating IGF-I
or OH levels. In contrast, using a solution-hybridization flu-
clease-protection assay, no changes in steady-state IGF-I
mRNA levels could be detected between controls or nephrec-
tomized animals [114]. However, an increase of immunoreac-
tive IGF-I in collecting ducts was observed five days after
uninephrectomy, but not after one or two days [114]. PDGF and
fibroblast growth factor (FGF) stimulate the release of IGF-I/
somatomedin C from fibroblasts in vitro [115]. IGF-I itself is
only a weak mitogen for fibroblasts, but can act synergistically
with EGF to induce proliferation [116]. Furthermore, fibro-
blasts produce different IGF-binding proteins [117]. The pro-
duction of these proteins is also under hormonal control. The
possibility that fibroblasts secrete and respond to IGF-I and
IGF-binding proteins, in an autocrine/paracrine manner, indi-
cates the potential of complex interactions between tubular
epithelium and fibroblast. Considering all these finds, there is
reasonable evidence that IGF-I plays some role in the process
of compensatory renal enlargement.
Transforming growth factors (TGFs)
Transforming growth factor a (TGFa), a 50 amino acid
peptide, shares 40% sequence homology with EGF [118, 119].
TGFa binds to the EGF-receptors and phosphorylates tyrosine
residues [120]. TGFa is able to induce autosynthesis as well as
activation of protein kinase C-induced synthesis of TGFa.
Transmembrane forms of TGFa can activate the EGF-receptor
and might play an adjunctive role in cell-cell contact and
interactions between different types of cells [121]. Although
initially found in virally transformed cells, there is increasing
evidence that TGFa is also produced by non-transformed cells.
For example, TGFa is synthesized and secreted by activated
macrophages [122]. BSC-1 cells seem not to produce TGFa,
whereas normal human kidney express mRNA transcripts for
TGFa [51]. Recent preliminary data applying rabbit anti-TGFa
antisera to histologic tissues have immunolocalized TGFa to
cortical collecting ducts of the rat kidney [123]. Intra-aortic
infusions of TGFa accelerate renal repair and recovery after
experimental ischemic injury to the kidney [124]. Whether
TGFa plays any role in the physiological regulation of renal
enlargement is unknown.
TGFI3 is a homodimer consisting of two disulfide-linked
chains of 12,500 Mr, and is not related to TGFa [125—128].
TGFf31, originally purified from platelets and kidney [127, 128],
is virtually produced by all cells. More recently, TGFI32, with a
different N-terminal amino acid sequence, and heterodimers
(TGFp1 .2) consisting of one TGF1 and one TGF/32 chain,
have been described [126]. Monkey BSC-1 tubular cells in
culture secrete TGF/32 [129]. TGF/3s, similar to other polypep-
tide growth factors, are synthesized as larger secretory precur-
sors which are then cleaved into smaller fragments [130].
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TGF2 and TGFf31.2 have probably a more restricted tissue
distribution than TGFp1. The TGFJ3s are members of a larger
family of growth inhibitory factors [130, 1311.
Two distinct types of TGF/3 receptors have been character-
ized: the type I TGF/3 receptor is a disulfide-linked complex of
565 to 615,000 Mr with a Kd of 50 to 500 p, and the smaller
type II TGF3 receptor with a Kd of 50 M and a molecular
weight of 85 to 110,000 Mr [132, 133]. Although many tissues
seem to have both types of receptors, only the type II receptor
is expressed in rat myoblasts. The functional difference be-
tween the receptors is not known. TGF/3 receptors have no
tyrosine activity and are not down regulated after ligand bind-
ing. TGF/3 has complex effects on the proliferation and differ-
entiation of cells [134]. TGFI3 can either stimulate or inhibit
proliferation depending on the cell type, growth conditions and
presence of other growth factors. TGFI3 stimulates the prolif-
eration of AKR-2B cells in monolayers, and fibroblasts in
soft-agar [135]. Treatment of AKR-2B cells with TGFf3 stimu-
lates the early induction of c-sis and the corresponding secre-
tion of a PDGF-like factor into the supernatant. Moreover,
immediate early gene expression is also induced with co-
culture. These data suggest that TGFf mediated mitogenesis in
this cell line occurs through the induction of c-sis with subse-
quent autocrine proliferation through PDGF. Where the prolif-
eration of epithelial cells is concerned, including renal proximal
tubular cells, TGFp has mainly inhibitory effects [58, 129].
TGF/3, insulin, and hydrocortisone together induce hypertro-
phy in BSC-1 cells, whereas insulin and hydrocortisone alone
are mitogenic for this cell line, suggesting that the presence of
TGFJ3, in culture, transfigures proliferative growth into hyper-
trophy [58]. In the culture of proximal tubule cells, TGF/3
promotes a morphologic change from monolayers into solid
clusters of cells [136]. The change in appearance of cells is
associated with alterations in the composition of the extracel-
lular matrix [136]. TGFJ3 also stimulates transcription, synthe-
sis, and secretion of procollagens type I, III, IV and fibronectin
[137, 138]. Furthermore, TGFI3 inhibits matrix degradation by
inhibiting the secretion of proteases as well as increasing the
synthesis of protease inhibitors. TGF3 can also directly stimu-
late the activity of the mouse a2(I) procollagen promoters as
well as the fibronectin promoter [139]. In addition, TGF/3 may
have effects on the post-translational levels of collagens. TGF3
increases the expression of cell membrane receptors specific for
cell adhesion proteins linking the extracellular matrix to the
cytoskeleton of the cell [140]. These changes of the extracellu-
lar matrix might facilitate hypertrophic enlargement and the
arrest of proliferation.
Fibroblast growth factors
Acidic fibroblast growth factor (aFGF) and basic FGF
(bFGF) are members of a large family of related proteins
expressed in different tissues [141]. FGFs are strongly bound to
heparin and heparan sulfate. Basic pituitary FGF is a 146 amino
acid protein. Four molecular forms of bFGF can be co-ex-
pressed from one mRNA, in a hepatoma cell line by starting
translation at non-AUG codons [142]. bFGF isolated from
kidney shares homologous sequences with pituitary FGF. Re-
cently a cDNA sequence of the 130,000 Mr receptor for bFGF
was isolated from Swiss 3T3 cells [143].
Human aFGF is 155 amino acids in length. The coding region
for aFGF is interrupted by two introns [1443. Kidney FGF is
mitogenic for endothelial cells, smooth muscle cells, and fibro-
blasts. Although FGF has been shown to be mitogenic for some
epithelia, it is not known whether kidney FGF plays any role in
the autocrine/paracrine growth regulation of tubular cells. FGF,
however, might be involved in angiogenesis and differentiation
during renal organogenesis [1451.
Ammonia
It has been long known that chronic metabolic acidosis
induced in rats by feeding them NH4CI can lead to renal
hypertrophy [146]. An increase in the urinary excretion of acid
equivalents, induced by the metabolic acidosis, has been con-
sidered to be largely responsible for the renal hypertrophy,
according to the working hypothesis [147]. However, a recent
study demonstrated that NH4CI added to the medium of cul-
tured rabbit proximal tubule cells can directly induce cellular
hypertrophy in the absence of extracellular acidemia even when
the Na/H antiporter is inhibited by amiloride [148]. An
increase in protein synthesis and a decrease in protein degra-
dation were the cause for the NH4CI induced hypertrophy.
Although the mechanisms of NH4C1 on protein synthesis and
turnover remained to be established, this study suggests that an
increase in renal ammoniagenesis under special conditions in
vivo might directly stimulate renal hypertrophy rather than the
metabolic acidosis itself.
Other growth factors
Reducing extracellular potassium concentrations in cell cul-
ture or feeding rats a potassium-deficient diet can induce
cellular proliferation and activation of glyceraldehyde-3-phos-
phate dehydrogenase [149]. In elegant studies, Toback and
co-workers demonstrated that these effects are due to an
unknown mitogenic factor released by stimulated cells in an
autocrine manner [150]. Furthermore, a reduction in sodium
concentration in the culture medium to 130 m stimulated
proliferation of monkey kidney epithelial cells (BSC-1 cells),
but not fibroblasts. BSC-1 cells released autocrine growth
factors with the molecular weight of 6,200 and 9,000 Mr after
exposure to low concentrations of sodium [151, 1521. The low
sodium-induced growth factors are not identical with hitherto
characterized factors. Angiotensin II (Ang II) induces hyper-
trophy, but not mitogenesis in a proximal tubular cell line [60].
FACS analysis revealed that Ang TI-treated cells remained in
the G1-phase of the cell cycle. Adenosine diphosphate is
another strong mitogenic stimulus for BSC-l monkey kidney
cells [153]. Table 2 shows that cytokines released from macro-
phages/lymphocytes have at least in vitro modulatory effects on
growth and collagen secretion in a tubular epithelial cell lines.
Tamm-Horsfall glycoprotein, localized to the ascending limb of
Henle's loop, can also bind lymphokines like IL-l [154].
Whether cytokines released from tubulointerstitial macro-
phages/lymphocytes play any role in normal renal growth in
vivo is unclear.
Proto-oncogenes in growth regulatory mechanisms
The transforming oncogenes of retroviruses have homolo-
gous counterparts in normal cells [155]. These proto-oncogenes
appear to play a pivotal role in the regulation of eukaryotic
growth and differentiation [156, 157]. Proto-oncogene products
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Table 2. Effect of different cytokines on the cell cycle and collagen
secretion of cultured murine proximal tubule cells (MCT cells)
Collagen types
Cytokines I III IV V Proliferation
Interleukin I —— + — — +1—
Interleukin II — — — — — — — — —
EGF ++ +1— +1— ni. +++
PDGF ++ ni. ++ n.j. +
TGFI3 — + + +1—
yIFN n.j. ni. ni. ni.
Angiotensin II +1— n.j. ++ n.j. (hypertrophy)
act at different points in this complex growth control network
(Table 3). Proto-oncogenes can be grouped into different fami-
lies: some encode for growth factors like the c-sis oncogene
which produces the B-chain of PDGF; others, like c-erb A,
c-erb B, and c-neu, are related to growth factor receptors with
tyrosine kinase functions [155, 158]. Additional oncogenes like
c-src and c-abl are related to oncogenic tyrosine kinases lacking
a trarismembrane domain, and are probably involved in the
intracellular transduction of signals [159]. A group of oncogenes
(Ha-, Ki- and N-ras) encode for GTP-binding proteins with
GTPase activity, and might act as coupling factors in signal
transduction. Finally, distinct nuclear oncogenes, like c-myc,
c-fos and c-jun, are activated by many growth stimuli [157].
Some of these oncogenes encode proteins which, acting to-
gether, are fundamental transacting factors in the regulation of
other genes [157, 158j. They are also necessary for the re-entry
of rested cells from the G0 phase into the cell cycle [21].
Signal transduction pathways
Figure 1 gives an overview of signal transduction pathways
which might be involved in renal growth regulation. Each cell
type has a distinct pattern of receptors responding to growth
factors. The distribution of receptors, as indicated above, for
special growth factors along the nephron is heterogeneous.
Many of these receptors for growth factors share common
structural motifs [155], while curiously enough, the growth
factors themselves usually have quite diverse structures. While
such receptors can be arbitrarily distinguished by whether they
are coupled to GTP-binding proteins (G-proteins) or by whether
they have cytoplasmic tyrosine kinase activity, some receptors
seem to activate pathways that include both G-proteins and
protein kinases [157].
GTP -binding proteins (G-proteins) and cAMP
G-proteins are intracellular modulators that carry signaled
information from activated membrane receptors to effector
enzymes, orion channels [160]. Most extensively studied is the
adenylate cyclase system which is controlled by a stimulatory
G-protein (G) and inhibitory G-protein (G1) [1611. By linking G
and G1 to different receptors, adenylate cyclase can be stimu-
lated or inhibited as a result of ligand binding to a receptor
[162]. G-proteins are heterodimers consisting of three polypep-
tides: a GTP binding a-chain (39 to 52,000 Mr), a /3-chain (35 to
36,000 Mr), and a y-chain (8,000 Mr) which are membrane
Table 3. Oncogenes expressed during epithehal hypertrophy andlor
hyperplasia
encode for the B-chain of PDGF
encode for a truncated version of
the EGF receptor with
tyrosine protein kinase activity
a transmembrane protein with
tyrosine kinase activity
the oncogene product shares
more than 70% homology with
the tyrosine protein kinase
domain of the insulin receptor
relationship to angiotensin
receptor
transmembrane protein with
tyrosine kinase activity
receptor for colony-stimulating
factor on monocytes and tissue
macrophages
ras encoded proteins of c-Ki-ras
2 approximately 21 kD (p2lras)
c-N-ras bind guanine
nucleotides and have intrinsic
GTPase activity
share 35—85% with ras genes
c-fos protein forms with the c-jun
a heterodimer through a
leucine zipper domain. The
heterodimer transactivates
sequence-specific promotor
regions of DNA.
highly conserved 75 kD nuclear
DNA binding protein
expressed mainly in
hematopoietic cells
62—64 kD nuclear phosphoprotein
with DNA-binding properties
anchored, and contribute to the receptor recognition site [163].
At the present time nine genes encoding for a-subunits and two
for the /3-subunits have been isolated [160, 164]. Smaller GTP
binding proteins of 20 to 24,000 Mr are also products of c-ras
oncogenes [165].
Activation of a membrane receptor causes G-protein-recep-
tor interaction and accelerates the exchange of GTP for GDP
which is bound by the a-subunit of the oligomer [1661. A
lowering of the Mg + concentration is necessary for this
reaction step. Binding of GTP to the a-subunit results in a
release from G, chains, and subsequent alterations of the
target effector. In the termination step, GTP is hydrolyzed to
GDP, the a-subunit dissociates from the effector and reassoci-
ates with /3y-subunit [160—163]. Cholera toxin enhances adenyl-
ate cyclase activity through ADP-ribosylation of the a-subunit
Abbreviations are: + + +, strong stimulation; ++, medium stimula-
tion; +, weak stimulation; +7—, no change; —, weak inhibition; — —,
medium inhibition; —
— —, strong inhibition; n.j., not investigated.
Oncogenes encoding for
growth factors (Signals)
c-sis
Oncogenes related to growth
factor receptors (Receptors)
c-erb B
c-neu (c-erb B-2)
c-ros
c-mas
c-me s
c-fms
Oncogenes with protein kinase
activity without
transmembrane domain
(Transducers)
c-src
c-mos
Oncogenes related to G-
proteins (Modulators)
c-H-ras- 1
c-rho
Nuclear oncogenes (Targets)
c-fos
c-myb
c-myc
non transmembraneous tyrosine-
specific protein kinase (p60src)
serine/threonine protein kinase
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Fig. 1. A simplified schematic of signal transduction pathways involved in the regulation of hypertrophy and hyperplasia. After a growth factor
or cytokine binds to its receptor, a signal is transduced by G-proteins and/or protein kinases. Modulators and amplifiers of these effects can be
cAMP, 1P3, DAG, or Secondary signals are expressed by the activation of protein kinases like protein kinase C, tyrosine kinases or
cAMP-dependent kinases which transmit signals or phosphorylate protein factors that interact with promoter/enhancer regions of immediate early
genes. In the cascade of differential phosphorylation of target-proteins, phosphatases, which themselves are tightly regulated, might also play a
pivotal role. Protein products of early genes can act through leucine zipper, zinc fingers domains or helixmotifs as transacting factors for the
activation or repression of subsequent genes. Several signal pathways might simultaneously operate in parallel in or a non-linear fashion producing
cross-talk between the different systems.
of G5 [167, 168]. In contrast, pertussis toxin interacts with
cysteine residues of G1 by ADP-ribosylation, intercepting the
tranduction of inhibition to adenylate cyclase. Increasing levels
of cyclic AMP (cAMP) are mitogenic for 3T3 cells in synergy
with other growth factors [169]. PDGF can also induce an
accumulation of cAMP in fibroblasts. In the same cell type, a
stimulation of protein kinase C results in an increase in cAMP
in the presence of forskolin or cholera toxin [170, 171]. An
elevation of intracellular cAMP levels induces the phosphory-
lation of vimentin, an intermediate filament protein of 58,000
Mr, but not the phosphorylation of protein kinase C [172].
Recent findings indicate that cAMP can regulate gene expres-
sion through a 43,000 Mr transacting factor which binds to a 30
nucleotide cAMP response element (CRE) [173]. The purified
protein is phosphorylated by cAMP-dependent protein kinase
in vitro. In a model system of adenovirus transfected pheochro-
mocytoma PCI2 cells, cAMP-dependent protein kinase acti-
vates early E2a and E3 promoters [174]. CRE binding proteins
recognize the sequence cassette TGACGTCA, present in vari-
ous promoters including c-fos. Moreover, cAMP induces the
transcription of its own degrading enzyme, phosphodiesterase
[175]. PTH and magnesium-dependent adenylate cyclase activ-
ity in cortical membranes from kidneys with compensatory
renal enlargement are significantly lower than in controls [176].
A decrease in the activity of the cs-subunit from G was detected
by cholera toxin-mediated ADP-ribosylation, suggesting alter-
ations of G in compensatory renal enlargement [176].
Inositol-phosphatidyl systems
Many polypeptide growth hormones stimulate membrane
bound phospholipase C [177] which hydrolyzes phosphatidyl
inositol biphosphate to inositol triphosphate (1P3) and diacyl-
glycerol (DAG). Growth hormone binding to its specific recep-
tor activates phospholipase C in basolateral renal membrane
preparations from canine proximal tubule [1781. There is in-
creasing evidence that the receptor-mediated activation of
phospholipase C is transduced by a G-protein [179]. In many
cells, growth factor receptor-mediated phosphoinositide hy-
drolysis is insensitive to pertussis or cholera toxin treatment
[180]. In other tissues, however, pertussis toxin blocks hydrol-
ysis of inositol biphosphate and the increase in intracellular
Ca [181, 1821. The involvement of c-ras encoded proteins, as
G-proteins, associated with the phospholipase C system has
been emphasized in recent reports [183]. The ras proteins
belong to a family of closely related peptides known as p21
which are present in all eukaryotes [184]. Three ras genes
Modulators Secondary signals
Amplifiers
Immediate early genes
(c-fos, c-jun. c-myb, c-myc, Egr-1)
jL-LL-LL-L-L
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Fig. 2. Summary of events characterizing the hypertrophic or hyperplasic response of tubular cells in the tubulointerstitial microenvironment.
Pathophysiologic mechanisms, such as those described in Table I, might lead to autocrine or paracrine stimulation of tubular epithelial cells. Other
cell types resident in the tubulointerstitium, like fibroblasts, endothelium, resident macrophages and lymphocytes may all also participate and
modify the epithelial response through a complex cytokine network. Such cytokines might also have proliferative effects on tubular cells like EGF,
PDGF, or alternatively inhibit mitogenesis as in the case of IL-2 or TGF-/3 [41, 57, 86]. Additional factors like IGF and angiotensin II can induce
cellular hypertrophy in the absence of proliferation [60, 109]. Local actions of cytokines are under the influence of endocrine hormones which
modify local cytokine receptors expression, activation of Na/H antiporters as well as modify the general susceptibility of resident cell responses
to growth factors and cytokines. The specific or pivotal action of a single cytokine in this complicated network in vivo, however, is difficult to
establish, since the majority of data has been generated in cell culture systems applying single factor models. The exact selecting mechanisms
determining the degree of proliferation versus hypertrophic enlargement of renal cells are unknown, but might involve growth inhibitory factors
like TGF-f3 or prostaglandins [1, 41, 58, 129].
(H-ras-1, K-ras-2, and N-ras) and two pseudogenes (H-ras-2
and K-ras-l) have been identified [1851. Some mouse strains
have additional ras pseudogenes. Ras genes are members of a
highly conserved superfamily of genes, and other new classes of
ras related genes (rho) sharing 30 to 40% homology have been
characterized recently. Four exons of ras encode for p21.
K-ras-2 has two alternative fourth exons encoding for two
isomorphic forms of p21 with slightly different carboxyterminal
domains. Studies with a neutralizing anti-ras antibody revealed
that p21 proteins are necessary for the initiation of the S-phase
of the cell cycle, whereas the expression of c-ras oncogenes are
at their highest level in the middle-to-late G1-phase. Recently
the association of ras proteins, as transducers of phospholipase
C, have been questioned, since studies applying antibodies
against ras proteins in transformed cells demonstrate that ras
proteins are not directly involved in the regulation of phospho-
lipase C [186]. Purification and cloning of genes for phospholi-
pase C has revealed a rather unexpected complexity. Different
tissues have phospholipase C enzymes of different molecular
weights, suggesting multiple isoenzymes [187]. At the present
Resident
macrophages
Endothelium
TGFI3, IL-i, CSF,
PDGF
C®)
Growth inhibitory
factors, TGFp
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time four different genes for phospholipase C have been iden-
tified. Phospholipase C from rat kidney has a molecular weight
of 90,000 Mr [1881. Stable association of the PDGF-receptor
with phospholipase C and tyrosine phosphorylation of the
enzyme occurs after PDGF binding to its receptor [189]. 1P3
mobilizes intracellular Ca which can then bind to calmodu-
un, and subsequently activates calmodulin-dependent enzymes
[190—192]. DAG activates protein kinase C (PKC), which has a
high-affinity binding site for mitogenic phorbol esters [193].
PKC can bind to phorbol ester [194, 195]. Chronic treatment
with phorbol ester also leads to a decrease in specific binding
sites, and a decrease in PKC activity with a subsequent
desensitization of cells for growth stimuli [196]. On the other
hand, stimulating PKC by phorbol ester might lead to a phos-
phorylation of phospholipase C or the involvement of G-pro-
tein, resulting in unresponsive receptor stimulation. The pivotal
role of PKC in mitogenesis was additionally suggested by the
proliferative effect of synthetic l-oleoyl-2-acetylglycerol [195].
Molecular cloning as well as enzymological analysis has shown
a molecular heterogeneity of PKC in various tissues [1971.
Alpha, beta I, beta II, delta and theta subspecies are expressed
in many tissues, whereas gamma and epsilon are expressed only
in brain cells [197, 198]. Interestingly, the amino-terminal
domain of PKC contains repeats of cysteine-rich sequences
resembling zinc-finger motifs found in DNA-binding proteins
[199, 200].
There is hitherto, however, no evidence that PKC directly
binds to DNA. The kidney contains alpha, beta I and beta II
subspecies of PKC. PKC is found in tubular membranes [2011.
In vitro studies suggest that DAG can bind to cytosolic PKC,
inducing a shift to a membrane-associated form [202]. Other
findings reveal, however, that the cytosolic 50,000 Mr fragment
of PKC can phosphorylate proteins. This indicates that an
association with the membrane is not necessary for function. A
variety of growth factors, including PDGF [203] and vasopres-
sin [204], activate PKC in quiescent 3T3 fibroblasts, whereas
EGF and insulin do not stimulate PKC activity in these cells.
Activation of PKC is reflected by the phosphorylation of a
cellular protein with a molecular weight of 85,000 Mr [205].
PKC activity of brush border membranes, but not basolateral
membrane, from rat proximal tubular cells was significantly
increased 24 hours after unilateral nephrectomy [206] compared
to controls. Such findings suggest an involvement of the 1P3/
DAG pathway in compensatory renal enlargement. A 100%
increase in the concentration of DAG has been reported in
remnant kidney cortical tissue as soon as five minutes following
unilateral nephrectomy [207].
Protein kinases
The EGF-receptor has a basic tyrosine kinase domain related
to the p60 src protein [208, 209]. Similar tyrosine kinase
domains can be found in the receptors for PDGF, IGF I, insulin,
CSF-I as well as in receptor-like proteins encoded by the
oncogenes c-neu, c-ros, c-mes and c-kit. In addition, tyrosine
kinases exist which lack a transmembrane domain, and are,
therefore, linked to the membrane via myristylated glycine
[210]. These proteins can be formally considered as transduc-
ers. Recently, a new group of tyrosine kinases with a trans-
membrane domain, but without an external ligand binding
domain have been described [211]. The further generation of
multiple kinases is achieved by alternative splicing of single
genes [212]. Speculations have been made that as much as a
thousand different kinases are encoded by the mammalian
genome [213]. All of these proteins are probably modifying
signal transduction through interference with receptors and/or
G-proteins. C-terminal lysine residues of the tyrosine kinase
might also be involved in nucleotide binding since deletion of
lysine inactivates the enzyme. The further role of tyrosine
kinase in signal transduction is not clear. Tyrosine kinases can
be involved in receptor internalization. In PDGF-stimulated
3T3 cells, an 85,000 Mr phosphoprotein, was identified one
minute after treatment, suggesting this protein can be a sub-
strate for the tyrosine kinase of the PDGF receptor [211].
Furthermore, this 85,000 Mr phosphoprotein might map with
phosphatidylinositol (P1) kinase activity. The protein kinases
encoded by the oncogenes c-src and c-ros are also associated
with PT kinase activity [157, 159]. In EGF-stimulated cells, a 40
S ribosomal subunit protein called S6, with a molecular weight
of 33,000 Mr, is immediately phosphorylated [214—216]. This 33
to 35,000 Mr protein is detectable in medullary and cortical
thick ascending limbs, but not in proximal tubules in the rat
kidney [217]. EGF-induced a threefold increase in S6 kinase
phosphorylation after 30 minutes. Moreover, S6 phosphoryla-
tion increased in vivo four hours after uninephrectomy [218]. It
has been hypothesized that the phosphorylation of S6 alters the
affinity of the 40 S subunit for mRNA. This notion suggests the
possibility of gene regulation at a transcriptional level [2151.
The increased protein product might then perform by itself as a
transacting factor in the subsequent regulation of other genes.
Binding of insulin to its receptor also leads to the autophos-
phorylation of at least five tyrosine residues in the /3-subunit of
the receptor [219]. Autophosphorylation of the receptor is
necessary for the further phosphorylation of endogenous sub-
strates. Similar mechanisms of autophosphorylation upon sig-
nal stimulation have been described for PDGF, IGF-I, and EGF
receptors. Additional complexity is added by the fact that
different phosphoprotein phosphatases might be involved in the
regulation of protein phosphorylation [220].
The strict separation of the various signal transduction path-
ways, however, is somewhat artificial, and a lot of networking
between systems probably occurs [221]. PKC activation by
phorbols ester, for example, increases cAMP in the presences
of cholera toxin [222]. Vasopressin, in addition, which activates
PKC but normally not adenylate cyclase, also enhances cAMP
in 3T3 cells treated with forskolin or cholera toxin [2231. On the
other hand, treatment of certain tissues with dibutyryl cAMP or
theophyline can block phosphoinositide breakdown. Phosphor-
ylation of phospholipase C by cAMP dependent kinases has
been offered as the explanation. In addition to the above-
mentioned autophosphorylation of tyrosine in the EGF recep-
tor, serine and threonine residues are phosphorylated after
EGF stimulated PKC. A 32,000 Mr myristaylated PKC sub-
strate with a binding site for calmodulin has been described
[2241. In one proposed model, phosphorylation of this protein
leads to a release of bound calmodulin which, after Ca -
binding, can activate other enzymes linking PKC to Ca
activated processes [224]. The above-mentioned examples pro-
pose that interactive cross-talk between different transmem-
brane signalling systems can be involved in the regulation of
renal enlargement.
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Cellular pH and Na/H-antiporters
An enormous amount of work suggests that the Na/H-
antiporter is involved in mitogenesis [225, 2261 because alkalin-
ization has been traditionally considered a prerequisite for cell
proliferation. Several lines of evidence suggest the involvement
of Na/H exchange in this process: in controlled systems,
proliferation can be induced by alkalinization in the absence of
mitogens, also, most mitogenic substances stimulate Na/H
exchange (at least to some extent), inhibition of the Na/Ht
antiporter can hinder cellular enlargement, and enlargement is
impaired in mutant cells lacking the antiporter [227, 228]. PKC,
through stimulation by growth factors or directly by phorbol
ester, can likewise activate the antiporter. Other kinases may
also activate the antiporter. The molecular mechanisms sur-
rounding those events are not entirely clear.
Activation of the Na/H antiporter by growth factors in 3T3
fibroblasts is blocked by calcium antagonists and calmodulin
inhibitors, indicating involvement of calmodulin-dependent
transduction events. Direct phosphorylation of the antiporter
has also been proposed, since activation is reduced in ATP-
depleted cells and exchanger activity is increased in the pres-
ence of phosphatase inhibitors. Luminal Na/H exchanger
activity is decreased in proximal tubules with cAMP analogues,
implying that stimuli which increase cAMP provide a negative
regulation element for the antiporter [2291. The Na7H ex-
changer in apical membranes of the proximal tubule is under
dual phosphorylation control: protein phosphorylation medi-
ated by PKC stimulates the exchanger whereas cAMP-depen-
dent protein kinases inhibit activity by phosphorylation [2301.
The early activation of the Na/H exchanger is unaffected by
actinomycin D making regulation through de novo protein
synthesis unlikely. An increase in Na/H antiporter activity in
compensatory renal enlargement has been reported in several
species as early as within 15 minutes after uninephrectomy
[2071. Insulin and hydrocortisone in BSC-l cells increase
Na/H antiporter activity as well as induce proliferation [58].
By adding TGFf3 this stimulation can be converted into a
hypertrophic response without proliferation. Antiporter activ-
ity, however, remains stimulated under these new conditions.
Thyroid hormone increases Na/H exchange in renal proxi-
mal tubule membrane vesicles, offering one explanation for how
thyroid hormones can modify renal enlargement [2311. In iso-
lated perfused proximal tubules neither insulin nor IGF-I could
induce intracellular alkalinization of cells, whereas IGF-II
would [232]. The IGF-II alkalinization was associated with an
activated Na/H exchanger. Very recently, preliminary re-
suits suggest that the ipsolateral denervation associated with
unilateral nephrectomy might be a stimulus to the activation of
the antiporter in the contralateral remnant kidney. This in-
creased antiporter activity was thought to be mediated by
contralateral renal innervation through alpha 1 receptors [233].
Activation of the renal tubular antiporter seems, therefore, to
be a common event in both mitogenic and hypertrophic re-
sponses in the kidney.
More recently the general finding of Na/H antiporter
activity in renal enlargement has received increasing scrutiny
[234, 235], especially since more information has accumulated
indicating that amiloride has a variety of direct effects on
protein synthesis independent from the inhibition of the
Na/H antiporter. Amiloride directly blocks reticulocyte ly-
sate protein synthesis, interferes with DNA replication, influ-
ences topoisomerase II activity, and inhibits other transport
systems important for enlargement, like the Na-iinked
cotransport of amino acids [236]. In accordance with this view,
amiloride, but not hexamethylene amiloride, which has a much
higher affinity for the Na/H-antiporter, was shown to reduce
the compensatory increase in kidney weight and protein content
after uninephrectomy in mice. These findings indicate an inhi-
bition of protein synthesis by amiloride unrelated to antiporter
activity [237]. Mutant kidney pig epithelial cells (LLC-PK1) and
hamster CCL39 fibroblasts deficient of Na/H antiporter can
grow in medium containing bicarbonate, or at alkaline pH,
indicating that pH, and not the activation of the antiporter, is
essential for cell enlargement. Proliferation can be induced in
LLC-PK1 cells in the absence of Na/H exchange activity
[238]. IGF-I or insulin-induced hypertrophy was not different
between LLC-PKL mutants and wild type cells, suggesting that
antiporter activity is not necessary, either, for hypertrophy in
this model [239]. Taken together, these findings suggest that
activation of Na/H exchange is not a necessary prerequisite
for the enlargement of tubular cells. The exchanger might rather
be activated in parallel with other molecular mechanisms hav-
ing a more central role in the pluripotential growth process.
Immediate early genes
Stimulation of rested cells with serum or growth factors like
PDGF, FGF, or EGF induces, after one hour, the expression of
cellular oncogenes c-fos, c-jun and c-myc [240]. The activation
of c-jun A and c-fos precedes the induction of c-myc [241, 242].
After the addition of PDGF to quiescent fibroblasts, a 50-fold
increase in c-fos expression has been observed within 30
minutes, whereas c-myc RNA reaches a peak level after one to
two hours. More recently, a variety of other early genes,
induced by growth factors with similar kinetics to c-fos, have
been described [243, 244], including Krox-20, KC, JE, fos B,
Fra-l, E1A, c-myb, EGR and jun B. More than 70 different
genes induced by serum have been identified by differential
screening of cDNA libraries prepared from serum-stimulated
3T3 cells [245]. In terms of induction kinetics and RNA half-
lives, two groups of immediate early genes can be distin-
guished: one group represented by c-fos, are necessary for the
transition from the G0 and the G1-phase of the cell cycle, but are
not required for further progression. In contrast, genes like
c-myc are detectable at basal levels through all stages of the cell
cycle. These genes might be necessary for the transition from
G1 to the S phase. A common finding of immediate early genes
is their superinduction in the presence of the protein inhibitor
cycloheximide [246]. Superinduction after cycloheximide treat-
ment may be due to the inhibition of transcriptional blockers
and the enhancement of RNA stability by restricting de novo
synthesis of RNA degrading enzymes.
c-fos and c-jun
The c-fos gene has four coding exons resulting in a mRNA of
2.2 kb [247]. The fos promoter, localized upstream of the AUG
start site, is under complex positive and negative regulation
[248, 249]. C-fos protein, itself, has auto-negative feedback
transregulatory activity on its promoter [250]. The c-fos pro-
moter respond to agents which activate intracellular PKC or
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cAMP probably because it contains cAMP response elements
[251]. The c-fos protein forms a heterodimer with the protein
product of c-jun [252]. Association of the both proteins occurs
through a leucine zipper domain [253]. Dimerization is neces-
sary for subsequent DNA binding, but binding of the het-
erodimer to the specific DNA sequence TGACTCA present in a
variety of enhancers and promoters occurs via a domain distinct
from the leucine zipper [2541. While fos has an inherent
DNA-binding activity of its own, it still cannot alone form
homodimeric structures necessary for binding. Although site-
directed mutagenesis experiments demonstrated that the re-
gions in fos andjun responsible for DNA binding are conserved,
suggesting that fos and jun interact each with one-half site of the
target sequence [255, 256], recent evidence now reveals that the
binding is asymmetrical [257]. Protein products from newer
oncogenes related to fos orjun like fos B andjun B might form
leucine zipper in a similar fashion, or gene products of jun/fos
families might be even interchangeable in building the dimer
[258]. As already mentioned above, c-jun is a member of a
larger family, including jun B and jun D. All members share a
leucine zipper motif as well as DNA binding domains [258].
Similar to c-fos, c-jun is inducible by serum and growth factors
[259]. In contrast to fos, c-jun, however, can be identified at low
levels in uninduced cells, and is positively transautoregulated
by its product [260, 261]. This positive autoregulation could be
responsible for prolonging and extending transduction signals.
Thus, c-fos and c-jun are both independently induced by
different signal transduction systems after the stimulation of
cells with growth factors. Both genes are under control of
complex enhancer/promoter regulation. Their products subse-
quently form heterodimers through leucine zippers, and then
bind to specific sequences in enhancer/promoter regions of the
target genes. Other products of this family of genes might also
be involved in this process, or compete one with another for
dimerization [262]. It is obvious that such a complicated net-
work offers the opportunity of regulatory modulation at dif-
ferent levels.
c-myc
The murine c-myc has three exons of which the first exon
contains non-coding regulatory functions in mice, but has an
open reading frame in humans [263]. Transcription of the gene
initiates from two promoters named P1 and P2 which are
independently regulated and associated with a TATA box [264].
Regulation of c-myc occurs at transcriptional and post-tran-
scriptional levels. The c-myc gene is subject to negative and
positive regulation involving cis- and transacting factors [265,
266]. A variety of binding sites for activators and repressors
have been described in the large conserved c-myc promoter
region, in the 5' flanking region of the gene and in the first intron
[267]. Transcriptional elongation is negatively regulated by an
element inducing an intragenic pause in the first exon. It has
been postulated that different growth factors might regulate
c-myc transcription by several mechanisms [266]. PKC-depen-
dent pathways, for example, may activate transcription,
whereas cAMP-dependent pathways reduce intragenic pausing
[267]. This distinction, however, seems to be artificial since
different gene regulatory factors might not act independently.
The c-myc protein has a molecular weight of 62 to 64,000 Mr, is
phosphorylated, and has a half-life of 15 minutes. This c-myc
protein, when micro-injected, can induce DNA synthesis in
quiescent 3T3 cells [157].
Immediate early gene expression in renal growth
A 30-fold increase in the expression of c-myc transcripts has
been reported in kidneys of homozygous recessive C57BL/6J
mice which develop massively cystic nephrons. Interestingly
enough, the expression of S-phase-associated H4 RNA in-
creases only modestly, suggesting that elevated c-myc expres-
sion is not solely a marker for proliferation [268]. Mice positive
for c-myc transgene driven by an SV4O enhancer also develop
polycystic kidney disease, and die of renal failure between three
weeks and five months of age [269]. The proliferation of tubular
cells, subsequent to acute injury induced by folic acid treat-
ment, is associated with an increase in oncogene expression
[270, 271]. Si nuclease mapping demonstrates c-myc transcripts
which originate from the P1 and P2 initiation sites (with a biased
use of the P2 site) within two hours of folic acid treatment.
Nuclear run-off assays, however, reveal evidence for a parallel
increase in the blocking of transcriptional elongation. In con-
trast, c-fos transcription is induced after folic acid treatment
without affecting elongation block mechanisms. The authors
conclude from their study that the increase in c-myc expres-
sion, in contrast to c-fos, was probably due to post-transcrip-
tional mechanisms, since the amount of effective transcription
of c-myc remains constant despite the increase of c-myc tran-
scripts from the P1 and P2 sites [270]. A tenfold increase of
c-myc expression in renal cortex is observed during the repair
phase of ischemic acute renal failure [272]. Similar changes
have been detected after renal ischemia for c-fos and the
immediate early gene, Egr-l, which shares induction kinetics
with c-fos [871. The mitogens ADP, EGF, and PDGF stimulate
c-fos and c-myc expression in different tubular epithelial cell
lines.
Very modest increases in c-myc, c-H-ras and c-K-ras expres-
sion have been reported in compensatory renal hypertrophy
after uninephrectomy [273, 274]. Such observations, however,
may be related to operative stress, since oncogene expression
also increases in sham-operated animals. A more sustained
expression of c-H-ras and c-K-ras after unilateral nephrectomy,
however, has been described [275]. Although the in vivo studies
using total kidney RNA after uninephrectomy suggest that
oncogene expression does not change, cell-type specific
changes might exist which can only be addressed by the more
sensitive method of in situ hybridization. Moreover, the non-
specific increase in oncogene expression associated with sur-
gery and anesthesia may veil a slight, but biologically significant,
rise in immediate early gene expression after nephrectomy. Re-
cently, Sawczuk and co-workers found an transitory induction
of c-fos and c-myc in contralateral kidneys 15 minutes after
acute unilateral ureteral obstruction [276]. In this model, acute
unilateral obstruction led to a hypertrophic compensatory en-
largement response in the contralateral kidney [277]. Oncogene
expression was also observed in the obstructed kidney associ-
ated with tubular necrosis and stromal proliferation. These
results suggest that oncogene induction, after unilateral ureteral
obstruction, is associated with hypertrophy (contralateral kid-
ney) as well as with proliferation (ipsolateral kidney). In a more
recent study, Egr-1 expression was elevated 30 minutes after
contralateral nephrectomy when compared with sham-operated
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control animals [2781. These collective findings seem to indicate
that expression of some immediate early genes might be a
feature common to hypertrophic and proliferative responses in
tubular cells.
Regulation of renal growth by steroid hormones and retinoic
acid
Although androgens are not a prerequisite for compensatory
renal hypertrophy, these hormones might modulate the enlarge-
ment response of tubular cells [2791. Treatment of female mice,
but not of male mice, with exogeneous testosterone induces
hypertrophy in proximal tubules, whereas other organs, like the
liver, demonstrate a more combined effect of hypertrophy and
hyperplasia, suggesting tissue-specific enlargement effects of
androgens [280]. Impairment of compensatory renal hypertro-
phy in hypothyroidism has been described suggesting modifi-
cation of renal enlargement by thyroid hormones [2811. Al-
though thyroid hormones have other actions like stimulation of
the Na/H antiporter or induction of EGF-receptors (see
above), their main regulatory function is probably most visible
directly at the gene level [2821. Steroid hormones bind to special
steroid receptors. Structurally similar receptors exist for thy-
roid hormones [283]. The steroid-steroid receptor complex
subsequently binds to a special hormone response element
localized in promoter/enhancer regions of many genes [284].
Receptors for different steroids are structurally related, and
each receptor can be divided into six regions (A-F) depending
on the degree of amino acid sequence homology [285—287]. The
highly conserved C region contains the DNA binding domain,
and is 84 amino acids long in the androgen receptor. The
N-terminal A-B regions are variable in size between different
receptors, whereas the C-terminal E-F regions of the receptor
bind the appropriate hormone. Steroid-receptors bind in the
absence of hormone to a 90,000 Mr heat-shock protein which
masks its DNA-binding site. Steroid hormones promote disso-
ciation of this complex. The DNA-binding C-region of the
receptor consist of two zinc-finger motifs where each zinc atom
is surrounded by four cysteines [288]. Target gene specificity is
determined by these zinc-fingers. A model has been proposed in
which a dimer of receptors bind to the major grooves of four
helix turns of DNA [289]. Glucocorticoid response element,
with the conserved hexanucleotide sequence TGTTCT, can
also function as androgen response elements [290]. In addition,
hormone response elements have been described which are
unique to androgen-regulated genes [291].
A variety of genes and their gene products are induced in
proximal tubule kidney cells of mice treated with androgens.
Among them are enzymes like -glucuronidase, ornithine de-
carboxylase, and alcohol dehydrogenase [2921. Furthermore, a
43,000 Mr protein with unknown function encoded by the RP2
gene is induced in the kidney through testosterone treatment
[2931. In a similar manner, a polypeptide named kidney andro-
gen-regulated protein (KAP) is induced tenfold in proximal
convoluted tubular cells by androgen treatment. In addition to
transcriptional regulation, there is increasing evidence that
androgen inducible mRNA in kidney might be post-transcrip-
tionally modified in some way [280, 293]. It is, however,
unknown whether these post-transcriptional effects of steroids
are mediated by direct interaction of steroid-receptors and
RNA, resulting in stabilization of mRNA, or rather are indirect
through changes in transcription rates of other genes which
might, in turn, regulate the post-transcriptional event.
Retinoic acid potentiates the activity of EGF in rat kidney
fibroblasts probably by increasing the number of EGF-recep-
tors [294, 295]. Retinoic acid induces mitogenesis in rabbit
kidney epithelial cells, whereas retinol was without any effect
on proliferation [296]. Retinoic acid increased the size of domes
in confluent Madin-Darby canine kidney cells [2971. The dome
formation was associated with an increase in cAMP. Previous
experiments have demonstrated that retinoic acid stimulates
cAMP-dependent protein kinases A. Retinoic acid binding-
protein, which is identical or homologous to the cellular recep-
tors for retinoic acid (CRA), has been demonstrated in the urine
of living-related kidney donors after uninephrectomy [2981.
Furthermore, serum levels of vitamin A and retinol binding-
protein are increased after uninephrectomy. Since CRAs are
normally present in tubular cells, but do not appear in the urine,
detection of this protein in the urine after uninephrectomy
might reflect an increase in synthesis with spill over in the urine
[298]. CRAs are members of the steroid receptor superfamily
[283]. Alpha- and beta-receptors for retinoic acid have also been
described. The receptor interacts with a hormone response
element in target genes similar to other receptors of the steroid
superfamily. Retinoic acid induces enlargement hormone gene
expression, likewise suggesting the existence of HREs for the
retinoic acid receptors in the flanking region of the growth
hormone gene [299]. The alpha form of CRA can interact with
the beta form of the thyroid hormone receptor on thyroid
hormone response elements [300]. The retinoic acid-thyroid
hormone receptor heterodimer binds to different target DNA
sequences than the thyroid hormone receptor alone. It is
tempting to speculate that heterodimer formation might occur
between other members of the steroid receptor superfamily,
explaining the complexity of transcriptional control by these
hormones. The analogy of these mechanisms to the above-
described jun-fos interaction is obvious.
Gene expression and regulation of transcription in renal growth
Kidney mRNA is polyadenylated in a heterogeneous fashion
[301]. Around 50% of newly synthesized mRNA from kidneys
lack or have only very short poly(A) tails. No changes in size,
half-life, and distribution of total mRNA could be detected in
compensatory renal enlargement. The percentage of de novo
synthesized mRNA lacking polyadenylation, however, in-
creased within 60% minutes after uninephrectomy [301, 302].
Since poly(A) containing and poly(A)-deficient mRNAs are
homologous [303], it unclear whether these findings are in-
volved in regulatory mechanisms associated with compensatory
renal enlargement. Miller and McCarthy prepared radioactive
labelled eDNA from kidney after uninephrectomy and hybrid-
ized the cDNA to mRNA prepared from normal kidneys [304].
The maximal hybridization was unchanged compared to a
hybridization pattern from control cDNA to control mRNA.
The authors concluded that only few, if any, new species of
mRNA were expressed in compensatory renal hypertrophy.
However, these early applied hybridization techniques were
rather insensitive and could not measure small changes in
mRNA expression. Moreover, the overall hybridization pat-
tern, without actual cloning of the appropriate genes, could not
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detect small changes in rates of transcription or expression of
rare genes. Ouellette and co-workers, using nuclear run-off
assays, demonstrated an increase in transcription of precursor
rRNA 24 hours after uninephrectomy, whereas mRNA levels
coding for ribosomal proteins were unchanged [3051. There is
evidence, especially in androgen-induced hypertrophy, that
mRNA stabilization on a post-transcriptional level is important
[279]. It is, however, likely that mechanisms regulating post-
transcriptional events are themselves under transcriptional con-
trol [3061. Although proliferative growth is characterized by de
novo expression of different genes, including oncogenes, it is
not really clear whether new transcription of distinct genes
occurs during hypertrophy. No genes have been hitherto de-
scribed which are only associated with hypertrophy, but not
with mitogenesis. We believe that special genes likely exist
which are activated or deactivated only in the setting of
hypertrophy, and not in mitogenesis, since renal hypertrophy is
a highly complex enlargement response involving several reg-
ulatory factors clearly distinct from hyperplasia. In addition,
new genes which are specifically expressed at growth arrest,
and are down regulated after induction of mitogenesis, have
been recently described [307]. These genes, interestingly
enough, were not expressed at equal levels in all tissues of the
mouse. Recently a gene has been described which is only active
in normal liver tissues but not during regenerating growth of the
liver [308].
Early biochemical changes in renal growth
One of the earliest biochemical events in compensatory
hypertrophy is an increased of choline in phospholipids. It is
already detectable minutes after uninephrectomy [8, 309]. In
parallel, the activity of the key enzymes, choline kinase and
cholinephosphotransferase, are increased during the biosynthe-
sis of phoshophatidylcholine [3101. An increase, furthermore, in
phosphatidylcholine synthesis via the Kennedy pathway occurs
in hyperplasic forms of renal enlargement, like acute tubular
necrosis, or renal enlargement induced by potassium depletion
[311]. An increase in the synthesis of phospholipids may reflect
new membrane formation in growing kidney cells or modified
expression of membrane-bound enzyme activity [81. The mech-
anism of how growth factors stimulate phosphatidylcholine
synthesis is not known. However, de novo synthesis of key
enzymes and/or alterations in the membrane microenvironment
with activation of membrane-associated enzymes may be im-
portant after binding of growth factors to cellular receptors. An
increase of the enzyme ornithine decarboxylase (ODC), cata-
lyzing the first step in polyamine biosynthesis, has been de-
scribed after unilateral nephrectomy [15]. Pretreatment of rats
with difluormethylornithine, an inhibitor of ODC, did not influ-
ence renal hypertrophy after ablation, suggesting that this
enzyme is not directly involved in the mechanisms of compen-
satory renal hypertrophy [312]. The activities of various en-
zymes of the proximal tubule, including Na-K-ATPase [313,
314], aminopeptidases [3151, and the enzymes of gluconeogen-
esis [316], are increased in compensatory enlargement reflecting
final biochemical alterations which might lead to a form of
hypermetabolism [317], and contribute to the long-term pro-
gression of chronic renal failure in remnant kidneys. Prostaglan-
dins are likewise involved in the regulation of renal enlarge-
ment. Reduction in renal mass stimulates the synthesis of
pro staglandins [318, 319]. Furthermore, eicosanoids might be
responsible, in part, for the increase in renal blood flow and
glomerular filtration occurring after ablation of renal mass.
Treatment of uninephrectomized rats with indomethacin like-
wise abolished the increase in prostaglandin synthesis in com-
pensatory renal enlargement [320]. Growth factor activation of
phospholipase C and phospholipase A2 also releases arachi-
donic acid from membrane phospholipids and stimulates pros-
taglandin synthesis [182]. Purkerson et al reported increased
thromboxane B2 urinary excretion in rats with 1-1/3 nephrec-
tomy [321]. Treatment with OKY 1581, an inhibitor of throm-
boxane synthesis, resulted in better renal function and less
severe histological changes, but no effect on kidney size was
observed, indicating that, at least in this setting, thromboxanes
are not directly involved in compensatory renal enlargement.
Summary
Adult kidneys, which are principally composed of tubuloin-
terstitium, do not normally regenerate or expand their working
pool of functional cells at a very high rate. Loss of kidney
tissue, however, can lead to some compensatory renal enlarge-
ment. The catalytic forces initiating such exchanges have not
been fully articulated by current experimental endeavors. In-
creasing evidence, nevertheless, does suggest that factors other
than simple changes in renal hemodynamics may be involved in
this process. Different cellular elements in the tubulointerstitial
microenvironment probably modulate changes in tubular en-
largement or size through a complex cytokine network. Auto-
crine and paracrine stimulation of enlargement by different local
growth factors also seem to play a pivotal role. After binding to
cellular receptors, these factors activate signal transduction
pathways resulting in expression of immediate early genes,
which by themselves can synchronize the expression of subse-
quent genes through the medium of transacting factors. The
renal enlargement response can also be modified by endocrine
hormones that can activate such genes directly and/or stimulate
other adjunctive processes, like receptor expression for the
regional binding of growth factors. Furthermore, renal enlarge-
ment is under negative feedback of inhibitory factors like
TGF/3. It is possible, for example, that special genes exist
which are only expressed to arrest enlargement. It has been
further suggested that activation of the Na/H antiporter is a
common denominator in renal enlargement. Recent findings,
however, indicate that the activation of this antiporter is not
always necessary, and might rather be a parallel event rather
than a key phenomena in tubular enlargement. G0/G1 transition
of tubular cells seems to involve similar factors in tubular
hypertrophy and hyperplasia. The factors which are responsible
for the final determination of the enlargement pattern (hyper-
trophy vs. proliferation) are unknown. The separation between
hypertrophy and hyperplasia, although suggested by striking
differences in cellular regulation, may be somewhat artificial,
since responses leading to tubular enlargement also exist in
circumstances where hyperplasia and hypertrophy are com-
bined events. Recently it has been proposed that growth factors
stimulate gluconeogenesis in proximal tubular cells producing
hyperplasia, whereas factors inhibiting gluconeogenesis might
induce hypertrophy [811. Whether the common pathway mes-
sage of this intriguing hypothesis is correct still requires further
validation. The subsequent activation of structural genes, in-
414 Wolfand Neilson: TIN hypertrophy and hyperplasia
cluding collagen secretion, membrane enzymes, tubular hyper-
metabolism and induced immune mechanisms, are also impor-
tant. These latter factors tend to modify the development of
structural diversity and interstitial fibrosis over the longer time
frame of the compensatory responses producing enlargement.
The regulatory mechanisms of tubular enlargement are fasci-
natingly complex, and certainly many more informative molec-
ular processes will be described in the future.
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